Sangamo BioSciences | SGMO - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
Alaunos Therapeutics USD 1.29M 865K 2026-03
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Alterity Therapeutics Limited AUD 36.21M 18.58M 2025-12
Amgen USD 11.69B 2.5B 2026-06
Bayer EUR 29.71B 863M 2026-06
BioCryst Pharmaceuticals USD -454.29M 99.55M 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Cipla INR 344.32B 15.13B 2026-03
Clal Biotechnology ILS 121.41M 4.62M 2023-12
Compugen USD 95.35M 7.38M 2026-03
CSL USD 18.66B 2.75B 2025-12
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Grifols EUR 6.21B 133.12M 2025-12
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
J&J USD 84.97B 3.78B 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
Merck USD 41.93B 3.94B 2026-06
Novartis USD 41.95B 3.02B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 69.57B 3.24B 2026-06
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Tectonic Therapeutic USD 230.42M 20.91M 2026-03
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06